Guan Baoxiang, Yue Ping, Lotan Reuben, Sun Shi-Yong
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Oncogene. 2002 May 9;21(20):3121-9. doi: 10.1038/sj.onc.1205430.
Death receptor 4 (DR4; also called TRAIL-R1), a member of the tumor necrosis factor receptor superfamily, is a cell surface receptor that triggers the apoptotic machinery upon binding to its ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Although several chemotherapeutic agents were reported to induce DR4 expression, the mechanism of this effect remains largely unknown. To begin to understand its regulation, we cloned a 1.8 Kb 5'-flanking region of the human DR4 gene and identified several putative binding sites for transcription factors including activator protein 1 (AP-1). Among the three putative AP-1 binding sites, the site located at -350/-344 is functionally active as evidenced by a combination of electrophoretic mobility shift and luciferase reporter assays. The AP-1 activator phorbol 12-myristate 13-acetate (TPA) enhanced the binding of this DR4 AP-1 binding site to protein(s) in a nuclear extract from TPA-treated cells, increased luciferase activity of a reporter construct containing this site and induced DR4 expression at the transcription level. These results indicate that AP-1 regulates DR4 expression via the AP-1 binding site located at -350/-344. AP-1 has been implicated in many critical cellular processes including apoptosis, and is a major target of the c-Jun NH(3)-terminal kinase signaling pathway that is activated by many anticancer drugs. Therefore, our findings may increase the understanding of the mechanisms underlying AP-1-mediated apoptosis as well as drug-induced apoptosis.
死亡受体4(DR4;也称为TRAIL-R1)是肿瘤坏死因子受体超家族的成员,是一种细胞表面受体,与配体肿瘤坏死因子相关凋亡诱导配体(TRAIL)结合后可触发凋亡机制。尽管有报道称几种化疗药物可诱导DR4表达,但其作用机制仍不清楚。为了开始了解其调控机制,我们克隆了人DR4基因1.8 Kb的5'侧翼区域,并鉴定了几个转录因子的假定结合位点,包括活化蛋白1(AP-1)。在三个假定的AP-1结合位点中,位于-350/-344的位点具有功能活性,这通过电泳迁移率变动分析和荧光素酶报告基因分析得到证实。AP-1激活剂佛波酯12-肉豆蔻酸酯13-乙酸酯(TPA)增强了该DR4 AP-1结合位点与TPA处理细胞的核提取物中蛋白质的结合,增加了含有该位点的报告基因构建体的荧光素酶活性,并在转录水平上诱导了DR4表达。这些结果表明,AP-1通过位于-350/-344的AP-1结合位点调节DR4表达。AP-1参与了许多关键的细胞过程,包括凋亡,并且是许多抗癌药物激活的c-Jun NH(3)-末端激酶信号通路的主要靶点。因此,我们的发现可能会增加对AP-1介导的凋亡以及药物诱导的凋亡潜在机制的理解。